BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9349421)

  • 1. Immunoregulation of intraocular tumours.
    Niederkorn JY
    Eye (Lond); 1997; 11 ( Pt 2)():249-54. PubMed ID: 9349421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunopathology of intraocular tumour rejection.
    Niederkorn JY
    Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed cellular immunity in mice harboring intraocular melanomas.
    Niederkorn JY
    Invest Ophthalmol Vis Sci; 1984 Apr; 25(4):447-54. PubMed ID: 6608506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
    Ma D; Luyten GP; Luider TM; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
    Benson JL; Niederkorn JY
    Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity.
    Hussein MR
    Int J Exp Pathol; 2006 Jun; 87(3):163-76. PubMed ID: 16709225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.
    Kurosawa S; Harada M; Matsuzaki G; Shinomiya Y; Terao H; Kobayashi N; Nomoto K
    Immunology; 1995 Jun; 85(2):338-46. PubMed ID: 7642226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye.
    Niederkorn JY; Benson JL; Mayhew E
    Reg Immunol; 1990-1991; 3(6):349-54. PubMed ID: 2132760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
    Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
    J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight.
    Hussein MR
    Br J Dermatol; 2005 Jul; 153(1):18-21. PubMed ID: 16029321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
    Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.